This study is looking at how to best use escitalopram, a common medication for anxiety, in young people aged 12 to 17. Researchers want to see if using genetic information (pharmacogenetically-guided) to decide the dose of escitalopram is better than standard dosing. They will compare these two approaches to see if one works better and has fewer side effects for anxiety. To join, you must be 12-17 years old, speak English, and have a diagnosis of generalized, social, or separation anxiety disorder. The study will measure anxiety levels using a scale called the Pediatric Anxiety Rating Scale (PARS) over 12 weeks to see how well the treatments work. The study plans to enroll 132 participants.

Study design

This is a double-blind, randomized study with 132 participants. Participants will be randomly assigned to receive either standard or pharmacogenetically-guided escitalopram dosing.

What's involved

You would participate in this study for 12 weeks. Your anxiety levels will be measured using the Pediatric Anxiety Rating Scale (PARS) at the beginning and at the end of the study.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, the Pediatric Anxiety Rating Scale severity score, is measured up to Week 12 or early termination.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.